Traws Pharma, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic.
Latest period: Q3 2025.
-
Symbol
-
TRAW on Nasdaq
-
Location
-
Newtown, PA
-
Fiscal year end
-
31 December
-
Latest financial report
-
13 Nov 2025
Quick Takeaways
- TRAW - Traws Pharma, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q3 2025.
- Headline metric: Return On Equity -1060%.
What Changed
- Return On Equity YoY change: <span class="text-green-600">+680%</span>.
- Most recent SEC facts end date: 10 Nov 2025.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original Filing
Latest SEC snapshot (2025-11-10) highlights Return On Equity -1059.6%, Return On Assets -124.5%, and Current Ratio 1.22x.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
46.8/100
Caution
Confidence low
Return On Equity
-1060%
Metric score 0.0/100
Return On Assets
-125%
Metric score 0.0/100
Financial Health
- Current Ratio
- 1.22x
Strengths
Current Ratio and NetIncomeLoss YoY
Watchpoints
Return On Equity and Return On Assets
Key metrics snapshot
Return On Equity
-1060%
YoY: +680%
Industry median:
-43%
(n=675)
View history
Return On Assets
-125%
YoY: +164%
Industry median:
-47%
(n=673)
View history
Current Ratio
1.22x
YoY: +14%
Industry median:
3.39x
(n=667)
View history
NetIncomeLoss YoY
53%
YoY:
Industry median:
-0.93%
(n=641)
View history
Profitability
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Return On Equity
|
-1060%
|
+680%
|
-43%
(n=675)
|
Q3 2025
|
Q3 2025
|
%
|
|
Return On Assets
|
-125%
|
+164%
|
-47%
(n=673)
|
Q3 2025
|
Q3 2025
|
%
|
Financial Health
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Current Ratio
|
1.22x
|
+14%
|
3.39x
(n=667)
|
Q3 2025
|
Q3 2025
|
x
|
Growth
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
NetIncomeLoss YoY
|
53%
|
|
-0.93%
(n=641)
|
Q3 2025
|
Q3 2025
|
%
|
Share Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Entity Common Stock, Shares Outstanding
|
7,990,867
|
+164%
|
Q3 2025
|
Q3 2025
|
shares
|
|
Common Stock, Shares, Outstanding
|
7,131,151
|
+136%
|
Q3 2025
|
Q3 2025
|
shares
|
|
Common Stock, Value, Issued
|
$71,000
|
+137%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Weighted Average Number of Shares Outstanding, Basic
|
8,818,859
|
+817%
|
Q3 2025
|
Q3 2025
|
shares
|
|
Weighted Average Number of Shares Outstanding, Diluted
|
8,818,859
|
+817%
|
Q3 2025
|
Q3 2025
|
shares
|
Additional Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
General and Administrative Expense
|
$9,665,000
|
-11%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Operating Income (Loss)
|
$15,785,000
|
+89%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Earnings Per Share, Basic
|
-5
|
+87%
|
Q3 2025
|
Q3 2025
|
USD/shares
|
|
Earnings Per Share, Diluted
|
-5
|
+87%
|
Q3 2025
|
Q3 2025
|
USD/shares
|
|
Other Assets, Current
|
$92,000
|
-73%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Assets, Current
|
$9,625,000
|
+7.9%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Property, Plant and Equipment, Net
|
$7,000
|
-42%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Other Assets, Noncurrent
|
$240,000
|
+23900%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Assets
|
$12,443,000
|
+39%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Accounts Payable, Current
|
$5,105,000
|
-6.7%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Employee-related Liabilities, Current
|
$774,000
|
+34%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Accrued Liabilities, Current
|
$2,782,000
|
+5%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Liabilities, Current
|
$7,887,000
|
-5.5%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Liabilities
|
$7,898,000
|
-28%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Accumulated Other Comprehensive Income (Loss), Net of Tax
|
$6,000
|
|
Q3 2025
|
Q3 2025
|
USD
|
|
Retained Earnings (Accumulated Deficit)
|
$632,541,000
|
-2.1%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
|
$4,545,000
|
|
Q3 2025
|
Q3 2025
|
USD
|
|
Liabilities and Equity
|
$12,443,000
|
+39%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Common Stock, Shares Authorized
|
250,000,000
|
0%
|
Q3 2025
|
Q3 2025
|
shares
|
|
Common Stock, Shares, Issued
|
7,131,151
|
+136%
|
Q3 2025
|
Q3 2025
|
shares
|
|
Common Stock, Par or Stated Value Per Share
|
0.01
|
0%
|
Q3 2025
|
Q3 2025
|
USD/shares
|
|
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
|
$6,420,000
|
+19%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
|
$13,270,000
|
+53%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Preferred Stock, Shares Issued
|
7,440
|
0%
|
Q3 2025
|
Q3 2025
|
shares
|
|
Preferred Stock, Shares Authorized
|
5,000,000
|
0%
|
Q3 2025
|
Q3 2025
|
shares
|
|
Preferred Stock, Shares Outstanding
|
6,737
|
-9.4%
|
Q3 2025
|
Q3 2025
|
shares
|
|
Amortization of Intangible Assets
|
$14,000
|
|
Q3 2025
|
Q3 2025
|
USD
|
|
Share-based Payment Arrangement, Expense
|
$735,000
|
-47%
|
Q3 2025
|
Q3 2025
|
USD
|
|
Preferred Stock, Par or Stated Value Per Share
|
0.01
|
0%
|
Q3 2025
|
Q3 2025
|
USD/shares
|
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric |
Weight |
V1 threshold |
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
Explore related SEC datasets